

## CME POSTTEST

---

Record your answers below and send along with the CME Registration Form/Evaluation Answer Form.

1. Which of the following is **not** included in the histologic diagnostic criteria of UIP?
  - a. Temporally heterogeneous fibrosis, with areas of normal lung
  - b. Active fibrosis (fibroblastic foci)
  - c. Microscopic honeycombing
  - d. Pigment-laden macrophages
  
2. Acute exacerbations in IPF are:
  - a. More common in patients with severe disease
  - b. Associated with high mortality
  - c. Caused by infection
  - d. Responsive to augmented immunosuppression
  
3. Typical HRCT findings in IPF include:
  - a. Pleural effusion
  - b. Central lobular nodules
  - c. Subpleural honeycombing
  - d. All of the above
  
4. Which of the following is **not** a major diagnostic criterion for IPF in the absence of a surgical lung biopsy?
  - a. HRCT: bibasilar reticular abnormalities with minimal ground-glass opacities
  - b. Duration of illness > 5 years
  - c. Evidence of restriction and/or impaired gas exchange
  - d. Transbronchial lung biopsy (BAL) that does not support an alternative diagnosis
  
5. Surgical lung biopsy may **not** be required when which of the following is true?
  - a. Classic IPF clinical presentation
  - b. Typical clinical and HRCT presentations of IPF
  - c. Classic IPF clinical presentation with a typical chest x-ray
  - d. Typical IPF chest x-ray with supporting laboratory results
  
6. Which of the following statements is true?
  - a. Baseline DL<sub>CO</sub> is a useful prognostic indicator
  - b. All IPF patients follow a slow and steady decline in lung function
  - c. UIP pattern found on biopsy is a clear indication of a poor prognosis
  - d. A and C

7. Which of the following baseline measures is not associated with survival?
- a. Mean pulmonary artery pressure
  - b. Desaturation (< 88%) during 6MWT
  - c.  $V_D/V_T$  measurements
  - d.  $DL_{CO}$
8. Which of the following statements does **not** apply to azathioprine and prednisone for IPF?
- a. No proven benefit shown in recent IPF trials
  - b. Combination therapy with proven efficacy in the treatment of IPF
  - c. 2000 ATS/ERS consensus suggested therapy
  - d. Potentially significant treatment toxicity
9. The current lung transplant guidelines use a lung allocation score that includes evaluation of which of the following?
- a. Wait time
  - b. Mortality based on projected pretransplant 1-year survival
  - c. Mortality based on projected posttransplant 1-year survival
  - d. B and C
10. When should IPF patients be referred for a lung transplant evaluation?
- a. At time of diagnosis
  - b. When  $DL_{CO} < 40\%$  predicted
  - c. After a 10% decline in lung function
  - d. After patient demonstrates impaired exercise capacity
11. Nonpharmacologic therapies for IPF patients include which of the following?
- a. Pulmonary rehabilitation
  - b. End-of-life care
  - c. Supplemental oxygen
  - d. All of the above